Melanoma was where the checkpoint inhibitor era proved itself — ipilimumab's 2011 approval showed for the first time that durable long-term survival in metastatic disease was achievable, not just tumor shrinkage. The 10-year survival data that followed from CheckMate 067 (nivolumab + ipilimumab) showed roughly 43% of patients with metastatic melanoma alive at 10 years — a number that would have been incomprehensible in 2010. The 2026 research agenda is built on that foundation but aimed squarely at what it left unresolved: the 57% who aren't surviving long-term, patients who progress after checkpoint inhibitors, and the earlier-stage populations where preventing recurrence is a far more tractable goal than treating metastatic disease.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Melanoma 10-year survival with combination nivolumab + ipilimumab has reached 43% — a landmark in oncology. In 2026, trials are pushing further: the personalized mRNA vaccine mRNA-4157/V940 (KEYNOTE-942) reduced recurrence or death by 44% vs. pembrolizumab alone in resected high-risk melanoma, and Phase 3 enrollment is underway. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, showed 31.5% ORR in heavily pretreated patients. LAG-3 inhibitor relatlimab + nivolumab (Opdualag) is approved and being extended to earlier-stage disease. The field is also validating perioperative immunotherapy for resectable Stage III/IV disease to address the recurrences that ultimately kill patients who appeared cured.
ClinicalMetric Analysis
- The 43% 10-year survival with nivolumab + ipilimumab applies to a clinical trial-eligible population that is systematically healthier than real-world metastatic melanoma patients. CheckMate 067 excluded patients with active brain metastases, poor performance status (ECOG 2+), and significant organ dysfunction. Real-world metastatic melanoma patients often have all three. The 43% is the ceiling of what's achievable in optimal conditions — it communicates that durable long-term survival is possible, not that it's probable for an unselected population presenting to a community oncologist.
- TIL therapy's manufacturing timeline requires bridging therapy planning to start simultaneously with apheresis scheduling — not after. Lifileucel's apheresis-to-infusion timeline is 4–6 weeks. In rapidly progressing melanoma after PD-1 and BRAF therapy failure, that window is clinically significant. The bridging therapy question — what to give during TIL manufacturing without compromising infused T cell function or causing toxicities that delay the infusion — is a real clinical planning problem. Centers offering lifileucel should have a standardized bridging protocol, not a case-by-case improvisation at apheresis.
- Neoadjuvant immunotherapy before Stage III/IV resection is conceptually superior to adjuvant therapy alone — and trials are confirming it. Treating before surgery allows the immune system to see tumor antigen in situ, generating a broader and more durable T cell response than post-surgical adjuvant therapy where most antigen has been removed. Pathological complete response (pCR) rate at surgery is emerging as an early surrogate for long-term RFS in this setting — similar to how pCR guides adjuvant decisions in breast cancer. Patients with resectable Stage III melanoma should specifically ask whether neoadjuvant immunotherapy trials are available before defaulting to upfront surgery.
Where the Standard of Care Stands
For unresectable or metastatic melanoma, the two primary first-line options are combination nivolumab + ipilimumab (CheckMate 067: 10-year OS 43%, mPFS 11.5 months) or pembrolizumab monotherapy (KEYNOTE-006: 5-year OS 38%). These aren't trivially different choices — combination therapy has higher response rates and more durable long-term survival in responders, but also significantly higher rates of serious immune-related adverse events (59% Grade 3/4 with combination vs. 17% with pembrolizumab). For patients with PD-L1 ≥1% tumors, the benefit-risk calculation is close enough to require individual discussion.
For BRAF V600-mutant melanoma (approximately 50% of cases), targeted therapy with BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) provides rapid responses in 65–70% of patients — useful for patients with high tumor burden who need quick disease control — but median PFS is 12–15 months before resistance emerges. Sequencing BRAF-targeted therapy vs. immunotherapy is an ongoing area of investigation.
TIL Therapy and CAR-T: Cellular Approaches for Refractory Disease
Lifileucel (Amtagvi, Iovance Biotherapeutics) received FDA approval in February 2024 for unresectable or metastatic melanoma after failure of PD-1 and BRAF-targeted therapy — the first tumor-infiltrating lymphocyte therapy approved for any solid tumor. The C-144-01 trial showed an ORR of 31.5% in patients with median 3 prior lines of therapy, including complete responses in 4.3% of patients. For a population that had essentially no good options, this is meaningful.
TIL therapy involves harvesting a patient's own tumor-specific T cells from a surgical biopsy, expanding them ex vivo to billions of cells, then reinfusing them following lymphodepleting chemotherapy. The process takes 4–6 weeks from biopsy to infusion and requires specialized manufacturing infrastructure. Clinical trials building on lifileucel are testing next-generation TIL products with engineered cytokine support (IL-2 variants) and shorter manufacturing timelines.
The PRAME-targeting TCR-T cell therapy IMA203 (Immunocore) showed meaningful responses in melanoma patients with prior checkpoint inhibitor failure — an ORR of 33% in the Phase 1/2 expansion cohort. This is particularly notable because it works in patients where PD-1 and CTLA-4 blockade have already failed, suggesting a distinct and non-overlapping mechanism of T-cell re-engagement. Phase 3 enrollment is underway for IMA203 in melanoma.
Personalized mRNA Cancer Vaccines: The KEYNOTE-942 Result
The KEYNOTE-942 trial results represent one of the most significant melanoma findings of the past several years. The trial randomized 157 patients with resected high-risk Stage IIB–IV melanoma (no evidence of disease after surgery) to receive either mRNA-4157/V940 (a personalized neoantigen vaccine) plus pembrolizumab or pembrolizumab alone. At 2-year follow-up, the combination reduced the risk of recurrence or death by 44% — recurrence-free survival of 78.6% vs. 62.2% for pembrolizumab alone.
How this vaccine works: each patient's tumor biopsy is whole-genome sequenced, an algorithm selects up to 34 neoantigens (mutation-derived peptides predicted to generate T-cell responses) specific to that patient's tumor, and a custom mRNA construct encoding those neoantigens is manufactured for that individual patient — typically within 8 weeks of biopsy. The vaccine primes and expands neoantigen-specific T-cell responses that complement pembrolizumab's checkpoint blockade. Phase 3 (KEYNOTE-942P3) is now enrolling high-risk resected melanoma patients across multiple tumor types including NSCLC and bladder cancer.
Next-Generation Checkpoint Approaches
Opdualag (relatlimab + nivolumab) received FDA approval in 2022 for unresectable or metastatic melanoma based on RELATIVITY-047 showing a doubling of median PFS compared to nivolumab alone (10.1 vs. 4.6 months). LAG-3 is expressed on exhausted T cells and functions as a co-inhibitory receptor — blocking it alongside PD-1 rescues a population of T cells that PD-1 blockade alone cannot. Trials are now extending Opdualag to adjuvant treatment of resected high-risk melanoma (RELATIVITY-098).
Intralesional therapies targeting accessible tumor deposits — the approach of injecting immunostimulatory agents directly into palpable lesions to generate systemic immune responses — are an active research area. Talimogene laherparepvec (T-VEC, oncolytic herpes simplex virus) is approved. Next-generation oncolytic viruses (RP1, HF10, CAVATAK), TLR agonists (tilsotolimod, CMP-001), and STING agonists are all in trials for melanoma, often in combination with systemic checkpoint inhibitors. The hypothesis is that local tumor killing and innate immune activation provides antigens and an inflammatory context that enhances systemic PD-1 inhibitor responses.
Trial Eligibility: What Determines Your Options
- Adjuvant/perioperative trials: Resected Stage IIB–IV melanoma, no evidence of disease, adequate organ function, ECOG performance status 0–1. Most require BRAF mutation testing at enrollment. The KEYNOTE-942P3 neoantigen vaccine trial requires fresh tumor tissue from the resection.
- Metastatic trials: Unresectable Stage III or Stage IV; prior therapy requirements vary significantly — some checkpoint combination trials enroll treatment-naive patients, while TIL and TCR-T cell trials typically require prior PD-1 inhibitor failure. Brain metastases are included in some trials if controlled and stable.
- BRAF status: Required in virtually all trials. Approximately 50% of melanomas carry BRAF V600E or V600K. BRAF-positive patients may be asked to have failed BRAF-targeted therapy before entering certain immunotherapy trials, or may be specifically enrolled for combination strategies.
- TIL/cellular therapy trials: These require accessible tumor for harvest (usually a surgical procedure), 4–6 week manufacturing lead time, and fitness for lymphodepleting chemotherapy. Autoimmune disease, immunodeficiency, and certain prior therapies are common exclusion criteria.